Stanford University Expert to Host Pulmonary Hypertension Webinar for Patients and Caregivers on October 30, 2012
A Free Service Provided by the Scleroderma Research Foundation with support from Gilead Sciences and MedImmune
SAN FRANCISCO, Oct. 26, 2012 /PRNewswire-USNewswire/ — The nonprofit Scleroderma Research Foundation (SRF) will welcome Roham Zamanian, MD, FCCP to present “Pulmonary Hypertension as a Complication of Scleroderma: A Guide for Patients and Caregivers” on October 30, 2012 at 11 a.m. PDT. This free webinar is intended to help viewers to better understand the disease as well as what is being done to find a cure and what new treatments are on the horizon.
Pulmonary arterial hypertension is one of the leading causes of death for patients with scleroderma, a disease that literally means “hard skin,” but oftentimes affects internal organs with life-threatening consequences. Approximately four out of five scleroderma patients are women with onset between the ages of 20 and 50, but the disease also strikes men and children across all ages and ethnic boundaries.
“This will be the seventh webinar in our series,” explains SRF Executive Director Amy Hewitt. “Our goal is not only to educate scleroderma patients, but also to raise awareness and provide a valuable library of resources for those who care for them.”
Dr. Zamanian, is Director of the Adult Pulmonary Hypertension Clinical Service at Stanford Hospital and Clinics. His career has focused on translational and clinical research relating to pulmonary vascular diseases with focus on pulmonary arterial hypertension. Stanford receives funding from the SRF to support their expanding patient clinic.
Tuesday, October 30, 2012 from 11:00 a.m. – 12:00 p.m. PDT. The Webinar will be available for later viewing on the SRF website.
Register online at www.sclerodermaRESEARCH.org.
About Scleroderma Research Foundation:
The SRF is America’s leading nonprofit investor in scleroderma research. It was founded in San Francisco in 1987 by scleroderma patient Sharon Monsky who lost her battle to the disease in 2002. Monsky’s legacy lives on through the organization, chaired by Luke Evnin, Ph.D., managing partner of MPM Capital, one of the world’s largest dedicated investors in life sciences.
The Foundation’s collaborative approach is enabling leading scientists to work together and develop an understanding of how scleroderma begins, how it progresses and what can be done to slow, halt or reverse the disease process.
SOURCE Scleroderma Research Foundation